Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Authors : Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber Rd, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart-Gebhart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, Mcfadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr
Year : 2021
Journal : N Engl J Med
Volume : 384
Pages : 2394-2405

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis.

Authors : Tagliamento M, Agostinetto E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, Punie K, Westphalen CB, Morgan G, Pronzato P, Del Mastro L, Poggio F, Lambertini M
Year : 2021
Journal : Crit Rev Oncol Hematol
Pages : 103365

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.

Authors : Zahavi T, Salmon-Divon M, Salgado R, Elkin M, Hermano E, Rubinstein AM, Francis PA, Di Leo A, Viale G, de Azambuja E, Ameye L, Sotiriou C, Salmon A, Kravchenko-Balasha N, Sonnenblick A
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 67

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.

Authors : Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S
Year : 2021
Journal : Expert Opin Biol Ther
Volume : 21
Pages : 945-962

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.

Authors : Martel S, Lambertini M, Agbor-Tarh D, Ponde NF, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A, Maurer C, Piccart-Gebhart M, Moreno-Aspitia A, Desmedt C, Di Cosimo S, de Azambuja E
Year : 2021
Journal : J Natl Compr Canc Netw
Volume : 19
Pages : 181-189

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.

Authors : R Ferreira A, Ferreira S, Lambertini M, Maurer C, Martel S, Costa L, Ponde N, de Azambuja E
Year : 2021
Journal : Eur J Cancer
Volume : 144
Pages : 351-359

Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.

Authors : Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, Gnant M, Günthert A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauerc M, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radosevic-Robin N, Sager P, Steyerova P, Tausch C, Peeters MTFDV, Weber WP, Cardoso MJ, Poortmans P
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : e18-e28

Impact of HIV infection on baseline characteristics and survival of women with breast cancer.

Authors : Brandão M, Bruzzone M, Franzoi MA, de Angelis C, Eiger D, Caparica R, Piccart-Gebhart M, Buisseret L, Ceppi M, Dauby N, Carrilho C, Lunet N, de Azambuja E, Lambertini M
Year : 2021
Journal : AIDS
Volume : 35
Pages : 605-618

Impact of ARTs on oncological outcomes in young breast cancer survivors.

Authors : Condorelli M, De Vos M, Lie Fong S, Autin C, Delvigne A, Vanden Meerschaut F, Wyns C, Imbert R, Cheruy C, Bouziotis J, de Azambuja E, Delbaere A, Lambertini M, Demeestere I
Year : 2021
Journal : Hum Reprod
Volume : 36
Pages : 381-389

STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.

Authors : Sonnenblick A, Agbor-Tarh D, de Azambuja E, Hultsch S, Izquierdo M, Liu M, Pruneri G, Harbeck N, Piccart-Gebhart M, Moreno-Aspita A, Granit RZ, Rouas G, Fahoum I, Sotiriou C
Year : 2021
Journal : Int J Cancer
Volume : 148
Pages : 1529-1535

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Authors : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Year : 2021
Journal : J Clin Oncol
Volume : 39
Pages : 1448-1457

Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.

Authors : Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, Partridge AH, Lambertini M
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : e303-e313

Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.

Authors : Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, Criscitiello C, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100104

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.

Authors : Agostinetto E, Eiger D, Punie K, de Azambuja E
Year : 2021
Journal : Curr Oncol Rep
Volume : 23
Pages : 57

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

Authors : Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber Rd, Piccart-Gebhart M
Year : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 287-296

The Exciting New Field of HER2-Low Breast Cancer Treatment.

Authors : Eiger D, Agostinetto E, Saude Conde R, de Azambuja E
Year : 2021
Journal : Cancers (Basel)
Volume : 13

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.

Authors : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Year : 2021
Journal : Breast
Volume : 57
Pages : 86-94

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.

Authors : Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Clin Invest
Pages : e13535

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.

Authors : Caparica R, Bruzzone M, Agostinetto E, de Angelis C, Fêde Â, Ceppi M, de Azambuja E
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100066

Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean.

Authors : Werutsky G, Barrios CH, Cardona AF, Albergaria A, Valencia A, Ferreira CG, Rolfo C, de Azambuja E, Rabinovich GA, Sposetti G, Arrieta O, Dienstmann R, Rebelatto TF, Denninghoff V, Aran V, Cazap E
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : e488-e500